RDHL Key Statistics, Chart & Performance
The current stock price of RDHL is 1.36 USD. In the past month the price increased by 14.77%. In the past year, price decreased by -78.88%.
RDHL Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to RDHL. When comparing the yearly performance of all stocks, RDHL is a bad performer in the overall market: 94.33% of all stocks are doing better.
RDHL Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to RDHL. Both the profitability and financial health of RDHL have multiple concerns.
RDHL Financial Highlights
Over the last trailing twelve months RDHL reported a non-GAAP Earnings per Share(EPS) of -2.48. The EPS decreased by -100.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -45% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
RDHL Forecast & Estimates
RDHL Ownership
RDHL Latest News, Press Relases and Analysis
About RDHL
Company Profile
RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Company Info
REDHILL BIOPHARMA LTD-SP ADR
21 Ha'arba'a St.
TEL AVIV-YAFO 64739 IL
CEO: Dror Ben-Asher
Employees: 35
Phone: 97235413131
REDHILL BIOPHARMA LTD-SP ADR / RDHL FAQ
What does RDHL do?
RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
What is the stock price of REDHILL BIOPHARMA LTD-SP ADR today?
The current stock price of RDHL is 1.36 USD. The price increased by 2.26% in the last trading session.
Does REDHILL BIOPHARMA LTD-SP ADR pay dividends?
RDHL does not pay a dividend.
What is the ChartMill technical and fundamental rating of RDHL stock?
RDHL has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the Short Interest ratio of REDHILL BIOPHARMA LTD-SP ADR (RDHL) stock?
The outstanding short interest for REDHILL BIOPHARMA LTD-SP ADR (RDHL) is 436.62% of its float.